Interrogating disease clusters, multimorbidity and adverse outcomes in chronic kidney disease

探讨慢性肾脏病的疾病群、多发病和不良后果

• 批准号: MR/V001671/1
• 负责人: Michael Kenneth Sullivan
• 金额: $ 24.75万
• 依托单位: University of Glasgow
• 依托单位国家: 英国
• 项目类别: Fellowship
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FV001671%2F1
• 关键词: Interrogating; disease; clusters; multimorbidity; adverse

Background:People with kidney disease often have lots of health problems. They usually have more health problems than people whose kidneys work normally. They are more likely to have heart problems or die at a younger age. We do not know enough about why this is, or what can be done to stop these things from happening. Looking after patients with kidney disease and multiple health problems is complicated. It is not always possible to use tests and treatments that are used in people whose kidneys work normally. We need to understand better the effects of having multiple health problems together with kidney disease on people's lives.Aims:1) Find out the differences between people whose kidneys work normally and people with kidney disease.2) Among people with kidney disease and multiple health problems, find out the rates of the following health events: heart attacks, strokes, admissions to hospital and deaths.3) Among people with kidney disease and multiple health problems, find clusters of people who are most likely to have health events.4) Find the most effective way to predict which people with kidney disease and multiple health problems will have health events.Information Sources:This project will use information that has already been collected by doctors and researchers. The information about patients is held on computer systems. One source is a study called the UK Biobank, which involved 500,000 volunteers from across the UK. The people who took part had blood and urine tests and filled out questionnaires about their lives and medical problems. The second source is called the SAIL databank. This is where hospitals and GPs in Wales keep the information about 2.4 million people. The SCREAM cohort, based on 1.2 million people in Sweden, is the third source. The patients in all three sources cannot be identified because the information is anonymous.Benefits from the Planned Programme of Research:We will find people with kidney disease and multiple health problems who are more likely to have health events than others. If we can identify them early, they could be given better treatment. We might be able to keep them healthy for longer or find certain patients in whom more research needs to be done.Patients have been involved in our research from the start, helping us plan the project. However, we will not be collecting new information from patients. Instead, we will be using the data from four million people whose data has already been collected. Patients therefore will not need to spend extra time with researchers for the main part of our project. The information they have already given will make the research possible and they will be involved later, helping us to use the results of our research to help patients.

背景：肾病患者通常有许多健康问题。他们通常比肾脏正常工作的人有更多的健康问题。他们更有可能有心脏问题或在年轻时死亡。我们不知道为什么会这样，或者可以做些什么来阻止这些事情发生。照顾肾病和多种健康问题的患者是复杂的。它并不总是可能使用的测试和治疗，用于人的肾脏正常工作。我们需要更好地了解患有多种健康问题和肾脏疾病对人们生活的影响。目的：1）找出肾脏正常工作的人与患有肾脏疾病的人之间的差异。2）在患有肾脏疾病和多种健康问题的人中，找出以下健康事件的发生率：心脏病发作、中风、住院和死亡。3）在患有肾病和多种健康问题的人中，发现最有可能发生健康事件的人群。4）找到最有效的方法来预测哪些患有肾脏疾病和多种健康问题的人将发生健康事件。信息来源：该项目将使用医生和研究人员已经收集的信息。病人的信息保存在计算机系统中。一个来源是一项名为英国生物银行的研究，该研究涉及来自英国各地的50万志愿者。参与者进行了血液和尿液测试，并填写了有关他们生活和医疗问题的问卷。第二个来源称为SAIL数据库。这是威尔士的医院和全科医生保存240万人信息的地方。第三个来源是基于瑞典120万人的SCREAM队列。由于信息是匿名的，所有三个来源中的患者都无法识别。计划研究计划的好处：我们将发现患有肾脏疾病和多种健康问题的人比其他人更容易发生健康事件。如果我们能及早发现他们，他们可以得到更好的治疗。我们也许可以让他们保持更长时间的健康，或者找到某些需要进行更多研究的患者。患者从一开始就参与了我们的研究，帮助我们规划项目。但是，我们不会从患者那里收集新的信息。相反，我们将使用已经收集的400万人的数据。因此，患者将不需要花费额外的时间与研究人员的主要部分，我们的项目。他们已经提供的信息将使研究成为可能，他们将在以后参与，帮助我们利用我们的研究结果来帮助病人。

项目成果

Additional file 1 of The presence and impact of multimorbidity clusters on adverse outcomes across the spectrum of kidney function

多发病群的存在及其对整个肾功能范围内不良结果的影响的附加文件 1

• DOI: 10.6084/m9.figshare.21456121
• 发表时间: 2022
• 作者: Sullivan M

Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study.

• DOI: 10.1093/ndt/gfab303
• 发表时间: 2022-01-25
• 期刊: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
• 作者: Sullivan MK;Lees JS;Drake TM;Docherty AB;Oates G;Hardwick HE;Russell CD;Merson L;Dunning J;Nguyen-Van-Tam JS;Openshaw P;Harrison EM;Baillie JK;ISARIC4C Investigators;Semple MG;Ho A;Mark PB
• 通讯作者: Mark PB

Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study.

• DOI: 10.1016/j.eclinm.2021.101030
• 发表时间: 2021-08
• 期刊: EClinicalMedicine
• 影响因子: 15.1
• 作者: Lees JS;Ho F;Parra-Soto S;Celis-Morales C;Welsh P;Sullivan MK;Jani BD;Sattar N;Lang NN;Pell JP;Webster AC;Mark PB
• 通讯作者: Mark PB

Multimorbidity, Polypharmacy, and COVID-19 infection within the UK Biobank cohort

英国生物银行队列中的多重发病、多重用药和 COVID-19 感染

• DOI: 10.1101/2020.06.10.20127563
• 发表时间: 2020
• 作者: McQueenie R

Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study.

• DOI: 10.1016/s0140-6736(21)00799-6
• 发表时间: 2021-07-17
• 期刊: Lancet (London, England)
• 作者: Drake TM;Riad AM;Fairfield CJ;Egan C;Knight SR;Pius R;Hardwick HE;Norman L;Shaw CA;McLean KA;Thompson AAR;Ho A;Swann OV;Sullivan M;Soares F;Holden KA;Merson L;Plotkin D;Sigfrid L;de Silva TI;Girvan M;Jackson C;Russell CD;Dunning J;Solomon T;Carson G;Olliaro P;Nguyen-Van-Tam JS;Turtle L;Docherty AB;Openshaw PJ;Baillie JK;Harrison EM;Semple MG;ISARIC4C investigators
• 通讯作者: ISARIC4C investigators